Compare Crocs, Inc. (CROX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Summit Therapeutics Inc — how do they compare? Crocs, Inc. trades at $129.95 (market cap $6.31B), while Summit Therapeutics Inc trades at $15.41 (market cap $12.06B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Crocs, Inc. is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CROX | SMMT | |
|---|---|---|
Market Cap | $6.31B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $26.98 |
52-Week Low | $73.39 | $12.55 |
Enterprise Value | $7.83B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $138.19, up 1.15% today, near its 52-week high. The stock shows bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $4.55 versus $4.35 expected. Revenue trends are stable around $4B annually, though 2025 net income was negative due to high taxes. Analysts maintain a buy-heavy consensus with a $140.43 price target.
Outlook is positive with robust profitability margins and valuation support, but risks include tax scrutiny from recent Malta office news and HEYDUDE brand weakness. The stock offers growth potential if execution improves, yet investors face volatility from guidance misses and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
